Autosomal Dominant Polycystic Kidney Disease

Effects of Epidermal Growth Factor in Polycystic Kidney Disease
Michael Kelsey
Kelsey_Michael_Presentation.ppt
KelseyM-Presentation2.ppt

Renal cysts and Tumors
Renal cysts and Tumors.ppt

Renal Pathology
Renal Pathology.ppt

Nephrology
Sharla Hays, M.D.
cystic_disease.ppt

Kidney Disease: Polycystic Kidney Disease
Benny DeShazer Jr
Kidney Disease: Polycystic Kidney Disease.ppt

Polycystic Kidney Disease
John Aris
Polycystic Kidney Disease.ppt

Congenital Renal Abnormalities
Scott Wenderfer, MD/PhD
Congenital Renal Abnormalities.ppt

Polycystic Kidney Disease is associated with Mitral Valve Prolapse
Polycystic Kidney Disease.ppt

Chronic Renal Failure
Valerie Kolmer RN BSN BC
Chronic Renal Failure.ppt

Urinary Path Review
Urinary Path Review.ppt

Human Genetics of Urinary Tract Malformation
Ali Gharavi, MD
Human Genetics of Urinary Tract Malformation.ppt

Genetics and Altered Immune Responses
Susan Wise, RNC, PhD
Immune-endo.ppt

Renal masses and cysts
J. Stuart Wolf, Jr., M.D.,
GUDis.KidneyUpperUT.ppt

Pathology Review Flash Cards Renal, LUT, Male Genital, Endocrine
Renal_male_endo.ppt

Renal Cell Carcinoma
Tim Fenske
Renal Cell Carcinoma.ppt

Genetics and Pathogenesis of Polycystic Kidney Disease
Maria Abreu
Genetics and Pathogenesis of Polycystic Kidney Disease .ppt

Left facial numbness
Ann Schmidt
Left facial numbness.ppt

ATP Synthase (Bovine F1-ATPase )
By Ashley, David, and Angela
ATP Synthase (Bovine F1-ATPase ) .ppt

Renal & Genitourinary Problems
Ravi Mangal Patel, MD
Renal & Genitourinary Problems.ppt

How Genes Are Transmitted from Generation to Generation
How Genes Are Transmitted.ppt
Latest 500 published articles

1. Progression of chronic kidney disease. Prevalence of anxiety and depression in autosomal dominant polycystic kidney disease.
2. Moxonidine-induced priapism in an autosomal-dominant polycystic kidney disease dialysis patient.
3. An 11-year-old child with autosomal dominant polycystic kidney disease who presented with nephrolithiasis.
4. Loss of GM3 synthase gene, but not sphingosine kinase 1, is protective against murine nephronophthisis-related Polycystic Kidney Disease.
5. Mucinous cystadenoma of the appendix mimicking polycystic kidney disease.
6. Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease.
7. Association of C49620T ABCC8 polymorphism with anthropometric and metabolic parameters in patients with autosomal dominant polycystic kidney disease: a preliminary study.
8. Medical therapy with tranexamic acid in autosomal dominant polycystic kidney disease patients with severe haematuria.
9. Chronic kidney disease progression in patients with autosomal dominant polycystic kidney disease.
10. A case of severe aortic valve regurgitation caused by an ascending aortic aneurysm in a young patient with autosomal dominant polycystic kidney disease and normal renal function.
11. Management of nephrolithiasis in autosomal dominant polycystic kidney disease - A single center experience.
12. Dissecting Aneurysm in A Patient with Autosomal Dominant Polycystic Kidney Disease.
13. Massive proteinuria and autosomal dominant polycystic kidney disease: a rare coincidence.
14. Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects.
15. Novel action of the chalcone isoliquiritigenin as a cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor: potential therapy for cholera and polycystic kidney disease.
16. Identification of novel mutations in Chinese Hans with autosomal dominant polycystic kidney disease.
17. Post transplant urinary tract infection in Autosomal dominant polycystic kidney disease a perpetual diagnostic dilema - 18-fluorodeoxyglucose - Positron emission computerized tomography - A valuable tool.
18. Psychonephrology: psychological aspects in autosomal dominant polycystic kidney disease.
19. Pericardial cyst: a novel extrarenal manifestation of autosomal dominant polycystic kidney disease.
20. A case of renal transcatheter arterial embolization with ethanol in autosomal dominant polycystic kidney disease for volume reduction.
21. Signal transducer and activator of transcription-6 (STAT6) inhibition suppresses renal cyst growth in polycystic kidney disease.
22. Hepatic and renal manifestations in autosomal dominant polycystic kidney disease: a dichotomy of two ends of a spectrum.
23. The prevalence of hypertension and nephrolithiasis in a sample of Iraqi patients with autosomal-dominant polycystic kidney disease.
24. Deceased donor kidney transplantation in autosomal dominant polycystic kidney disease: a single-center experience.
25. Anesthetic considerations in a patient of autosomal dominant polycystic kidney disease on hemodialysis for emergency cesarean section.
26. A non-synonymous mutation in the canine Pkd1 gene is associated with autosomal dominant polycystic kidney disease in Bull Terriers.
27. Anxiety, depression, and quality of life in patients with familial glomerulonephritis or autosomal dominant polycystic kidney disease.
28. Imaging approaches to patients with polycystic kidney disease.
29. Tranexamic Acid treatment of life-threatening hematuria in polycystic kidney disease.
30. Polycystic kidney disease and therapeutic approaches.
31. Molecular and cellular pathogenesis of autosomal dominant polycystic kidney disease.
32. Nephrotic syndrome and idiopathic membranous nephropathy associated with autosomal-dominant polycystic kidney disease.
33. Translation, cultural adaptation and aplication of a pain questionnaire for patients with polycystic kidney disease.
34. Systems biology approach to identify transcriptome reprogramming and candidate microRNA targets during the progression of polycystic kidney disease.
35. Tying TAZ and Nek1 into polycystic kidney disease through polycystin 2 levels.
36. [Co-inheritance of autosomal dominant polycystic kidney disease and sickle cell trait in African Americans].
37. [Autosomal dominant polycystic kidney disease and sickle cell trait].
38. [Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease].
39. Short-term reproducibility of ambulatory blood pressure monitoring in autosomal dominant polycystic kidney disease.
40. Molecular diagnosis of autosomal dominant polycystic kidney disease.
41. Hypoxia-inducible factor-1α (HIF-1α) and autophagy in polycystic kidney disease (PKD).
42. Urinary biomarkers for monitoring disease progression in the Han:SPRD-cy rat model of autosomal-dominant polycystic kidney disease.
43. [Caroli syndrome with autosomal recessive polycystic kidney disease].
44. Interpretation of renal volume in autosomal dominant polycystic kidney disease and relevant clinical implications.
45. Screening for intracranial aneurysm in 355 patients with autosomal-dominant polycystic kidney disease.
46. PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.
47. Transgenic overexpression of Anks6(p.R823W) causes polycystic kidney disease in rats.
48. Clinical aspects of autosomal recessive polycystic kidney disease.
49. Ectopic (pelvic) autosomal dominant polycystic kidney disease.
50. Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease.
51. Torres VE, Grantham JJ, Chapman AB, Mrug M, Bae KT, King BF Jr, Wetzel LH, Martin D, Lockhart ME, Bennett WM, Moxey-Mims M, Abebe KZ, Lin Y, Bost JE; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).
52. Epithelial-to-mesenchymal transition in cyst lining epithelial cells in an orthologous PCK rat model of autosomal-recessive polycystic kidney disease.
53. The cell biology of polycystic kidney disease.
54. Pioglitazone Attenuates Cystic Burden in the PCK Rodent Model of Polycystic Kidney Disease.
55. Endothelial cells from humans and mice with polycystic kidney disease are characterized by polyploidy and chromosome segregation defects through survivin down-regulation.
56. mTORC1/2 and rapamycin in female Han:SPRD rats with polycystic kidney disease.
57. Naturally occurring osmolytes modulate the nanomechanical properties of polycystic kidney disease domains.
58. Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease.
59. Global gene expression profiling in early-stage polycystic kidney disease in the Han:SPRD Cy rat identifies a role for RXR signaling.
60. MAP/ERK kinase kinase 1 (MEKK1) mediates transcriptional repression by interacting with polycystic kidney disease-1 (PKD1) promoter-bound p53 tumor suppressor protein.
61. [Relationship between renal size and blood pressure profile in patients with autosomal dominant polycystic kidney disease without renal failure].
62. Water prescription in autosomal dominant polycystic kidney disease: a pilot study.
63. Failure to ubiquitinate c-Met leads to hyperactivation of mTOR signaling in a mouse model of autosomal dominant polycystic kidney disease.
64. Inflammation, oxidative stress, and insulin resistance in polycystic kidney disease.
65. Thrombosis in inferior vena cava due to enlarged renal cysts in autosomal dominant polycystic kidney disease.
66. Use of endovascular stent-graft repair for type B aortic dissection in polycystic kidney disease.
67. Targeting B-Raf as a treatment strategy for polycystic kidney disease.
68. Blood pressure and survival in long-term hemodialysis patients with and without polycystic kidney disease.
69. Polycystic kidney disease in Han:SPRD Cy rats is associated with elevated expression and mislocalization of SamCystin.
70. Balancing the Wnts in polycystic kidney disease.
71. Aberrant regulation of planar cell polarity in polycystic kidney disease.
72. Improved prognosis in patients with autosomal dominant polycystic kidney disease in Denmark.
73. Nephrectomy in polycystic kidney disease before transplantation.
74. Images in clinical medicine. Autosomal dominant polycystic kidney disease.
75. Use of a body condition score technique to assess health status in a rat model of polycystic kidney disease.
76. Everolimus in patients with autosomal dominant polycystic kidney disease.
77. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.
78. Polycystic kidney disease protein fibrocystin localizes to the mitotic spindle and regulates spindle bipolarity.
79. Renal function and healthcare costs in patients with polycystic kidney disease.
80. The biomarker enriched proteome of autosomal dominant polycystic kidney disease cyst fluid.
81. Autosomal recessive polycystic kidney disease epithelial cell model reveals multiple basolateral epidermal growth factor receptor sorting pathways.
82. Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats.
83. Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases.
84. Birth of a healthy infant following preimplantation PKHD1 haplotyping for autosomal recessive polycystic kidney disease using multiple displacement amplification.
85. What is the role of somatic mutation in autosomal dominant polycystic kidney disease?
86. Molecular detection of autosomal-dominant feline polycystic kidney disease by multiplex amplification refractory mutation system polymerase chain reaction.
87. Autosomal dominant polycystic kidney disease with diffuse proliferative glomerulonephritis - an unusual association: a case report and review of the literature.
88. Intraperitoneal rupture of renal cyst in autosomal dominant polycystic kidney disease.
89. Early renal abnormalities in autosomal dominant polycystic kidney disease.
90. Correlation of kidney function, volume and imaging findings, and PKHD1 mutations in 73 patients with autosomal recessive polycystic kidney disease.
91. Knockdown of bicaudal C in zebrafish (Danio rerio) causes cystic kidneys: a nonmammalian model of polycystic kidney disease.
92. Activation of polycystic kidney disease-2-like 1 (PKD2L1)-PKD1L3 complex by acid in mouse taste cells.
93. Mechanisms of p53-mediated repression of the human polycystic kidney disease-1 promoter.
94. Use of a body condition score technique to assess health status in a rat model of polycystic kidney disease.
95. [Familial form of noncompaction cardiomyopathy associated with polycystic kidney disease].
96. Polycystic Kidney Disease, Autosomal Recessive.
97. Polycystic Kidney Disease, Autosomal Dominant.
98. Hypertension in autosomal dominant polycystic kidney disease.
99. Diagnosis and screening of autosomal dominant polycystic kidney disease.
100. Molecular advances in autosomal dominant polycystic kidney disease.
101. Autosomal dominant polycystic kidney disease.
102. Regulation of ciliary trafficking of polycystin-2 and the pathogenesis of autosomal dominant polycystic kidney disease.
103. A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease.
104. Refractory ascites due to portal hypertension in autosomal dominant polycystic kidney disease (ADPKD) patients successfully treated with peritoneal dialysis.
105. Novel targets for the treatment of autosomal dominant polycystic kidney disease.
106. Mycophenolate mofetil versus Rapamycin in Han: SPRD rats with Polycystic Kidney Disease.
107. Of mice and men: therapeutic mTOR inhibition in polycystic kidney disease.
108. A metabolomics approach using juvenile cystic mice to identify urinary biomarkers and altered pathways in polycystic kidney disease.
109. [Clinical analysis of a population with autosomal dominant polycystic kidney disease].
110. Hepato-renal pathology in pkd2ws25/- mice, an animal model of autosomal dominant polycystic kidney disease.
111. The HALT polycystic kidney disease trials: design and implementation.
112. Pkd1 transgenic mice: adult model of polycystic kidney disease with extrarenal and renal phenotypes.
113. Dynamic renogram with 99mTc DTPA in patient with adult polycystic kidney disease.
114. Polycystic kidney disease: inheritance, pathophysiology, prognosis, and treatment.
115. Autosomal dominant polycystic kidney disease and transplantation.
116. A mitotic transcriptional switch in polycystic kidney disease.
117. [Genetic analysis (PKD2) of autosomal dominant polycystic kidney disease].
118. Abnormalities in focal adhesion complex formation, regulation, and function in human autosomal recessive polycystic kidney disease epithelial cells.
119. The influence of renal manifestations to the progression of autosomal dominant polycystic kidney disease.
120. Polycystic kidney disease with coronary aneurysm and acute coronary syndrome.
121. PKHD1 sequence variations in 78 children and adults with autosomal recessive polycystic kidney disease and congenital hepatic fibrosis.
122. Autosomal dominant polycystic kidney disease: new treatment options and how to test their efficacy.
123. Polycystin-1 interacts with inositol 1,4,5-trisphosphate receptor to modulate intracellular Ca2+ signaling with implications for polycystic kidney disease.
124. Ultrasonography-guided intracystic injection of appropriate antibiotics: valuable for treatment of pyocyst in autosomal dominant polycystic kidney disease?
125. Cystic changes of breast in a family with autosomal dominant polycystic kidney disease.
126. Autosomal dominant polycystic kidney disease presenting with hepatic encephalopathy.
127. Nanomolar potency pyrimido-pyrrolo-quinoxalinedione CFTR inhibitor reduces cyst size in a polycystic kidney disease model.
128. Effect of pioglitazone on survival and renal function in a mouse model of polycystic kidney disease.
129. Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease.
130. Might there be an association between polycystic kidney disease and noncompaction of the ventricular myocardium?
131. Naturally occurring mutations alter the stability of polycystin-1 polycystic kidney disease (PKD) domains.
132. Analysis of causes of mortality in patients with autosomal dominant polycystic kidney disease: a single center study.
133. Autosomal dominant polycystic kidney disease: 2009 update for internists.
134. Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease.
135. Loss of Tsc1, but not Pten, in renal tubular cells causes polycystic kidney disease by activating mTORC1.
136. New mutations in the PKD1 gene in Czech population with autosomal dominant polycystic kidney disease.
137. [Genetic diagnosis of autosomal dominant polycystic kidney disease using multiplex-PCR].
138. Polycystic kidney disease in the medaka (Oryzias latipes) pc mutant caused by a mutation in the Gli-Similar3 (glis3) gene.
139. Cyst ablation using a mixture of N-butyl cyanoacrylate and iodized oil in patients with autosomal dominant polycystic kidney disease: the long-term results.
140. Polycystic Kidney Disease with Renal failure Presenting as Incarcerated Inguinal Hernia in the ED.
141. MKS3-related ciliopathy with features of autosomal recessive polycystic kidney disease, nephronophthisis, and Joubert Syndrome.
142. Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease.
143. Type II calcimimetics and polycystic kidney disease: unanswered questions.
144. Autosomal-dominant polycystic kidney disease.
145. Cyst infections in patients with autosomal dominant polycystic kidney disease.
146. Autosomal dominant polycystic kidney disease: the last 3 years.
147. A case for water in the treatment of polycystic kidney disease.
148. Advances in the pathogenesis and treatment of polycystic kidney disease.
149. Dietary soy protein selectively reduces renal prostanoids and cyclooxygenases in polycystic kidney disease.
150. 2008 Homer W. Smith Award: insights into the pathogenesis of polycystic kidney disease from gene discovery.
151. Prenatal MRI findings of polycystic kidney disease associated with holoprosencephaly.
152. Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks.
153. Renal injury is a third hit promoting rapid development of adult polycystic kidney disease.
154. Evaluation of nephrolithiasis in autosomal dominant polycystic kidney disease patients.
155. Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease.
156. Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD).
157. Polycystic kidney disease in adult Brazilian agoutis (Dasyprocta leporina).
158. Glis3 is associated with primary cilia and Wwtr1/TAZ and implicated in polycystic kidney disease.
159. Transcatheter arterial embolization therapy for a massive polycystic liver in autosomal dominant polycystic kidney disease patients.
160. The polycystic kidney disease 1 (Pkd1) gene is required for the responses of osteochondroprogenitor cells to midpalatal suture expansion in mice.
161. Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis.
162. TGF-beta mediated epithelial-mesenchymal transition in autosomal dominant polycystic kidney disease.
163. Current diagnostic evaluation of autosomal dominant polycystic kidney disease.
164. Autosomal dominant polycystic kidney disease: emerging concepts of pathogenesis and new treatments.
165. Activation of the AKT/mTOR pathway in autosomal recessive polycystic kidney disease (ARPKD).
166. Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease.
167. Evidence for pathogenicity of atypical splice mutations in autosomal dominant polycystic kidney disease.
168. DNA testing for live kidney donors at risk for autosomal dominant polycystic kidney disease.
169. Dyspnea in a 43-year-old woman with polycystic kidney disease.
170. Chronic blockade of 20-HETE synthesis reduces polycystic kidney disease in an orthologous rat model of ARPKD.
171. Microarray-based approach identifies microRNAs and their target functional patterns in polycystic kidney disease.
172. Gene expression in early and progression phases of autosomal dominant polycystic kidney disease.
173. Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis (ARPKD/CHF).
174. Unified ultrasonographic diagnostic criteria for polycystic kidney disease.
175. Disparate effects of roscovitine on renal tubular epithelial cell apoptosis and senescence: implications for autosomal dominant polycystic kidney disease.
176. The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD).
177. Structural and functional analyses of liver cysts from the BALB/c-cpk mouse model of polycystic kidney disease.
178. Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease.
179. Hydrolysis of insoluble collagen by deseasin MCP-01 from deep-sea Pseudoalteromonas sp. SM9913: collagenolytic characters, collagen-binding ability of C-terminal polycystic kidney disease domain, and implication for its novel role in deep-sea sedimentary particulate organic nitrogen degradation.
180. MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease.
181. Polycystic kidney disease.
182. Abnormal glyceraldehyde-3-phosphate dehydrogenase binding and glycolytic flux in Autosomal Dominant Polycystic Kidney Disease after a mild oxidative stress.
183. Retinoic acid-dependent activation of the polycystic kidney disease-1 (PKD1) promoter.
184. Acceleration of polycystic kidney disease progression in cpk mice carrying a deletion in the homeodomain protein Cux1.
185. Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease.
186. Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome.
187. [Biliptysis as the initial symptom of a rare complication of autosomal dominant polycystic kidney disease].
188. Adult polycystic kidney disease: a disorder of connective tissue?
189. Developments in the management of autosomal dominant polycystic kidney disease.
190. Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension.
191. Presence of de novo mutations in autosomal dominant polycystic kidney disease patients without family history.
192. Perinatal deaths in a family with autosomal dominant polycystic kidney disease and a PKD2 mutation.
193. Polycystic kidney disease: will it become treatable?
194. Aquaporin-11 knockout mice and polycystic kidney disease animals share a common mechanism of cyst formation.
195. 20-HETE mediates proliferation of renal epithelial cells in polycystic kidney disease.
196. [Acute pancreatitis and polycystic kidney disease].
197. [New therapeutic prospects in autosomal dominant polycystic kidney disease].
198. Mammalian target of rapamycin and caspase inhibitors in polycystic kidney disease.
199. Characterization of the renal cyst fluid proteome in autosomal dominant polycystic kidney disease (ADPKD) patients.
200. Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies.
201. Col2-Cre recombinase is co-expressed with endogenous type II collagen in embryonic renal epithelium and drives development of polycystic kidney disease following inactivation of ciliary genes.
202. Ciliary dysfunction in polycystic kidney disease: an emerging model with polarizing potential.
203. Nephrectomy in an autosomal recessive polycystic kidney disease (ARPKD) patient with rapid kidney enlargement and increased expression of EGFR.
204. A multiplexed quantitative strategy for membrane proteomics: opportunities for mining therapeutic targets for autosomal dominant polycystic kidney disease.
205. Contribution of renal innervation to hypertension in rat autosomal dominant polycystic kidney disease.
206. Src inhibition ameliorates polycystic kidney disease.
207. Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease.
208. LRRC50, a conserved ciliary protein implicated in polycystic kidney disease.
209. Coronary flow velocity reserve and carotid intima media thickness in patients with autosomal dominant polycystic kidney disease: from impaired tubules to impaired carotid and coronary arteries.
210. First description of polycystic kidney disease in a Portuguese journal.
211. Prevalence of cysts in seminal tract and abnormal semen parameters in patients with autosomal dominant polycystic kidney disease.
212. Hypertension in autosomal dominant polycystic kidney disease: observational study in 207 patients with a mean follow-up of 107 months.
213. Caspase-3 gene deletion prolongs survival in polycystic kidney disease.
214. Too much of a good thing: does Nek8 link polycystic kidney disease and nephronophthisis?
215. News from the cyst: insights into polycystic kidney disease.
216. Autosomal dominant polycystic kidney disease is associated with an increased prevalence of radiographic bronchiectasis.
217. Mechanoregulation of intracellular Ca2+ in human autosomal recessive polycystic kidney disease cyst-lining renal epithelial cells.
218. Variation in age at ESRD in autosomal dominant polycystic kidney disease.
219. Hypertension in autosomal dominant polycystic kidney disease.
220. Autosomal dominant polycystic kidney disease.
221. Morphological and functional features of hepatic cyst epithelium in autosomal dominant polycystic kidney disease.
222. Outcome of kidney transplantation in patients with polycystic kidney disease: a single center study.
223. Molecular diagnostics in autosomal dominant polycystic kidney disease: utility and limitations.
224. Renal and cardiac effects of antihypertensive treatment with ramipril versus metoprolol in autosomal dominant polycystic kidney disease.
225. Association of functional haem oxygenase-1 gene promoter polymorphism with polycystic kidney disease and IgA nephropathy.
226. Sirolimus ameliorates the enhanced expression of metalloproteinases in a rat model of autosomal dominant polycystic kidney disease.
227. Increased apoptosis and proliferative capacity are early events in cyst formation in autosomal-dominant, polycystic kidney disease.
228. Vasopressin directly regulates cyst growth in polycystic kidney disease.
229. Therapy for polycystic kidney disease? It's water, stupid!
230. Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.
231. Determinants of renal volume in autosomal-dominant polycystic kidney disease.
232. Haemoglobin and erythropoietin levels in polycystic kidney disease.
233. Increased occurrence of pericardial effusion in patients with autosomal dominant polycystic kidney disease.
234. Renal cyst infection in autosomal dominant polycystic kidney disease.
235. Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study.
236. Polycystic kidney disease and renal injury repair: common pathways, fluid flow, and the function of polycystin-1.
237. p21 is decreased in polycystic kidney disease and leads to increased epithelial cell cycle progression: roscovitine augments p21 levels.
238. The influence of endothelin-A receptor gene polymorphism on the progression of autosomal dominant polycystic kidney disease and IgA nephropathy.
239. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease.
240. Torres VE, King BF, Chapman AB, Brummer ME, Bae KT, Glockner JF, Arya K, Risk D, Felmlee JP, Grantham JJ, Guay-Woodford LM, Bennett WM, Klahr S, Meyers CM, Zhang X, Thompson PA, Miller JP; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).
241. Computed tomography evaluation of autosomal dominant polycystic kidney disease progression: a progress report.
242. Incident renal events and risk factors in autosomal dominant polycystic kidney disease: a population and family-based cohort followed for 22 years.
243. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes.
244. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort.
245. Bae KT, Zhu F, Chapman AB, Torres VE, Grantham JJ, Guay-Woodford LM, Baumgarten DA, King BF Jr, Wetzel LH, Kenney PJ, Brummer ME, Bennett WM, Klahr S, Meyers CM, Zhang X, Thompson PA, Miller JP; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).
246. Diagnostic approach in autosomal dominant polycystic kidney disease.
247. Non-Hodgkin's lymphoma in autosomal dominant polycystic kidney disease, 12 years after renal transplantation.
248. PKHD1 gene silencing may cause cell abnormal proliferation through modulation of intracellular calcium in autosomal recessive polycystic kidney disease.
249. Autosomal dominant polycystic kidney disease: an update.
250. Pathogenic sequence for dissecting aneurysm formation in a hypomorphic polycystic kidney disease 1 mouse model.
251. The 10 sea urchin receptor for egg jelly proteins (SpREJ) are members of the polycystic kidney disease-1 (PKD1) family.
252. Autosomal recessive polycystic kidney disease diagnosed in fetus.
253. Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease.
254. Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model.
255. Genetic interaction studies link autosomal dominant and recessive polycystic kidney disease in a common pathway.
256. Evaluating the clinical utility of a molecular genetic test for polycystic kidney disease.
257. [Aneurysms of the splenic artery and femoral-iliac arterial dissection in patients with autosomal dominant polycystic kidney disease].
258. Ambulatory blood pressure measurement in young normotensive patients with autosomal dominant polycystic kidney disease.
259. [Genetic diagnosis of polycystic kidney disease using single cell fluorescent polymerase chain reaction].
260. Characterization of cis-autoproteolysis of polycystin-1, the product of human polycystic kidney disease 1 gene.
261. Role of primary cilia in the pathogenesis of polycystic kidney disease.
262. Wnt signaling in polycystic kidney disease.
263. Genotype-phenotype correlations in autosomal dominant and autosomal recessive polycystic kidney disease.
264. Autosomal dominant polycystic kidney disease: time for a change?
265. Polycystic kidney disease.
266. Prime time for polycystic kidney disease: does one shot of roscovitine bring the cure?
267. Targeting dysregulated cell cycle and apoptosis for polycystic kidney disease therapy.
268. Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease.
269. [Bilateral renal cell carcinoma associated with polycystic kidney disease: case report and literature review].
270. Multiple cysts in the kidney and lungs in a patient with polycystic kidney disease and lymphangioleiomyomatosis.
271. Involvement of hypoxia-inducible transcription factors in polycystic kidney disease.
272. Study of candidate genes affecting the progression of renal disease in autosomal dominant polycystic kidney disease type 1.
273. Epidemiology and investigation of acute abdominal presentations in autosomal dominant polycystic kidney disease.
274. Retroperitoneoscopic nephrectomy as a second-line treatment after transarterial embolization for symptomatic autosomal dominant polycystic kidney disease.
275. [Molecular diagnosis of adult dominant polycystic kidney disease in the Canary Islands].
276. [Adult dominant polycystic kidney disease: molecular mechanisms and new therapeutic possibilities].
277. Beta-catenin signaling: linking renal cell carcinoma and polycystic kidney disease.
278. ACE gene I/D polymorphism and the presence of renal failure or hypertension in autosomal dominant polycystic kidney disease (ADPKD).
279. Endothelin B receptor blockade accelerates disease progression in a murine model of autosomal dominant polycystic kidney disease.
280. Retrospective analysis of factors affecting the progression of chronic renal failure in adult polycystic kidney disease.
281. Autosomal dominant polycystic kidney disease: pathophysiology and treatment.
282. Molecular and cellular pathogenesis of autosomal recessive polycystic kidney disease.
283. Galectin-3 associates with the primary cilium and modulates cyst growth in congenital polycystic kidney disease.
284. Research on autosomal dominant polycystic kidney disease in China.
285. DNA microsatellite analysis in families with autosomal dominant polycystic kidney disease (ADPKD): the first Polish study.
286. Early embryonic renal tubules of wild-type and polycystic kidney disease kidneys respond to cAMP stimulation with cystic fibrosis transmembrane conductance regulator/Na(+),K(+),2Cl(-) Co-transporter-dependent cystic dilation.
287. Regulation of mTOR by polycystin-1: is polycystic kidney disease a case of futile repair?
288. Pax2 gene dosage influences cystogenesis in autosomal dominant polycystic kidney disease.
289. [Giant aneurysm of the intracavernous internal carotid artery associated with autosomal dominant polycystic kidney disease: case report].
290. Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease.
291. Duodenal diverticulosis in autosomal dominant polycystic kidney disease.
292. A truncated polycystin-2 protein causes polycystic kidney disease and retinal degeneration in transgenic rats.
293. Influence of ACE I/D gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease: a meta-analysis.
294. The polycystic kidney disease-1 gene is a target for p53-mediated transcriptional repression.
295. Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease.
296. Volume progression in polycystic kidney disease.
297. Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis: summary statement of a first National Institutes of Health/Office of Rare Diseases conference.
298. [Planar cell polarity and polycystic kidney disease].
299. Increased water intake decreases progression of polycystic kidney disease in the PCK rat.
300. A hypomorphic mutation in the mouse laminin alpha5 gene causes polycystic kidney disease.
301. Development and characterization of a cholangiocyte cell line from the PCK rat, an animal model of Autosomal Recessive Polycystic Kidney Disease.
302. Volume progression in polycystic kidney disease.
303. Therapeutic approaches in autosomal dominant polycystic kidney disease (ADPKD): is there light at the end of the tunnel?
304. MEK inhibition holds promise for polycystic kidney disease.
305. Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease.
306. G8: a novel domain associated with polycystic kidney disease and non-syndromic hearing loss.
307. Renal and extrarenal manifestations of autosomal dominant polycystic kidney disease.
308. mTOR is out of control in polycystic kidney disease.
309. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease.
310. Primary cilia and regulation of renal Na+ transport. Focus on "Heightened epithelial Na+ channel-mediated Na+ absorption in a murine polycystic kidney disease model epithelium lacking apical monocilia".
311. Caroli's syndrome with autosomal recessive polycystic kidney disease in a two month old infant.
312. Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort.
313. Overexpression of PKD1 causes polycystic kidney disease.
314. Autosomal dominant polycystic liver disease in a family without polycystic kidney disease associated with a novel missense protein kinase C substrate 80K-H mutation.
315. PKD1 and PKD2 mutations in Slovenian families with autosomal dominant polycystic kidney disease.
316. Defining a link with autosomal-dominant polycystic kidney disease in mice with congenitally low expression of Pkd1.
317. Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells.
318. Loss of PKD1 and loss of Bcl-2 elicit polycystic kidney disease through distinct mechanisms.
319. What is the role of tubular epithelial cell apoptosis in polycystic kidney disease (PKD)?
320. Gas-forming infection in a renal cyst of a patient with autosomal dominant polycystic kidney disease.
321. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
322. Metastatic intracranial subdural empyema from renal cyst infection in autosomal dominant polycystic kidney disease.
323. Missense mutation in sterile alpha motif of novel protein SamCystin is associated with polycystic kidney disease in (cy/+) rat.
324. Heightened epithelial Na+ channel-mediated Na+ absorption in a murine polycystic kidney disease model epithelium lacking apical monocilia.
325. Multi-exon deletions of the PKHD1 gene cause autosomal recessive polycystic kidney disease (ARPKD).
326. Role of keratinocyte growth factor in the pathogenesis of autosomal dominant polycystic kidney disease.
327. Pretransplant bilateral hand-assisted laparoscopic nephrectomy in adult patients with polycystic kidney disease.
328. Increased activity of activator protein-1 transcription factor components ATF2, c-Jun, and c-Fos in human and mouse autosomal dominant polycystic kidney disease.
329. Autosomal dominant polycystic kidney disease showing rupture of a lateral ventral hernia following paralytic ileus.
330. Androgen receptor pathway in rats with autosomal dominant polycystic kidney disease.
331. Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease.
332. High-resolution renal sonography in children with autosomal recessive polycystic kidney disease.
333. An evolutionarily conserved coiled-coil protein implicated in polycystic kidney disease is involved in basal body duplication and flagellar biogenesis in Trypanosoma brucei.
334. Polycystic kidney disease prevented by transgenic RNA interference.
335. Transforming growth factor alpha (TGF-alpha) and other targets of tumor necrosis factor-alpha converting enzyme (TACE) in murine polycystic kidney disease.
336. Common regulatory elements in the polycystic kidney disease 1 and 2 promoter regions.
337. [Autosomal dominant polycystic kidney disease--research status and clinical manifestation].
338. Erythropoietin-producing renal cell carcinoma arising from autosomal dominant polycystic kidney disease.
339. Kinesin family member 12 is a candidate polycystic kidney disease modifier in the cpk mouse.
340. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat.
341. Mispolarization of desmosomal proteins and altered intercellular adhesion in autosomal dominant polycystic kidney disease.
342. Progressive loss of renal function is an age-dependent heritable trait in type 1 autosomal dominant polycystic kidney disease.
343. Information from your family doctor. Polycystic kidney disease (PKD).
344. Autosomal dominant polycystic kidney disease and pain: radiologist's perspective.
345. Vancomycin concentrations in autosomal dominant polycystic kidney disease.
346. PGD for autosomal dominant polycystic kidney disease type 1.
347. Renal concentrating capacity is linked to blood pressure in children with autosomal dominant polycystic kidney disease.
348. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease.
349. A microbial TRP-like polycystic-kidney-disease-related ion channel gene.
350. Biliary dysgenesis in the PCK rat, an orthologous model of autosomal recessive polycystic kidney disease.
351. Lowering of Pkd1 expression is sufficient to cause polycystic kidney disease.
352. The gene expression profile of cyst epithelial cells in autosomal dominant polycystic kidney disease patients.
353. Feline polycystic kidney disease mutation identified in PKD1.
354. Intraflagellar transport and cilia-dependent renal disease: the ciliary hypothesis of polycystic kidney disease.
355. Autosomal dominant polycystic kidney disease and pain - a review of the disease from aetiology, evaluation, past surgical treatment options to current practice.
356. Renal failure in a patient with autosomal dominant polycystic kidney disease and coexisting dermato-polymyositis: first report in the literature.
357. Prenatal sonographic patterns in autosomal dominant polycystic kidney disease: a multicenter study.
358. Orpk mouse model of polycystic kidney disease reveals essential role of primary cilia in pancreatic tissue organization.
359. The intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease.
360. Conjugated linoleic acid reduces parathyroid hormone in health and in polycystic kidney disease in rats.
361. Renal vascular resistance and renin-angiotensin system in the pathogenesis of early hypertension in autosomal dominant polycystic kidney disease.
362. Thrombosis in inferior vena cava (IVC) due to intra-cystic hemorrhage into a hepatic local cyst with autosomal dominant polycystic kidney disease (ADPKD).
363. Development of multiorgan pathology in the wpk rat model of polycystic kidney disease.
364. Repeat imaging for intracranial aneurysms in patients with autosomal dominant polycystic kidney disease with initially negative studies: a prospective ten-year follow-up.
365. A transcriptional network in polycystic kidney disease.
366. PKD2 mutations in a Czech population with autosomal dominant polycystic kidney disease.
367. PKHD1 protein encoded by the gene for autosomal recessive polycystic kidney disease associates with basal bodies and primary cilia in renal epithelial cells.
368. The autosomal recessive polycystic kidney disease protein is localized to primary cilia, with concentration in the basal body area.
369. Autosomal dominant polycystic kidney disease (ADPKD, MIM 173900, PKD1 and PKD2 genes, protein products known as polycystin-1 and polycystin-2).
370. Chymase-like angiotensin II-generating activity in end-stage human autosomal dominant polycystic kidney disease.
371. Ablation of symptomatic cysts using absolute ethanol in 11 patients with autosomal-dominant polycystic kidney disease.
372. A polycystin-1 multiprotein complex is disrupted in polycystic kidney disease cells.
373. Adult polycystic kidney disease in patients on haemodialysis in the south of Brazil.
374. Murine models of polycystic kidney disease: molecular and therapeutic insights.
375. Beta4 integrin and laminin 5 are aberrantly expressed in polycystic kidney disease: role in increased cell adhesion and migration.
376. No effect of enalapril on progression in autosomal dominant polycystic kidney disease.
377. Autosomal dominant polycystic kidney disease: modifier genes and endothelial dysfunction.
378. Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease.
379. Influence of ACE (I/D) and G460W polymorphism of alpha-adducin in autosomal dominant polycystic kidney disease.
380. Bilateral popliteal aneurysms complicating adult polycystic kidney disease in a patient with a marfanoid habitus.
381. Malignancy risk in patient with neurofibromatosis and autosomal dominant polycystic kidney disease.
382. Angiotensinogen and angiotensin II type 1 receptor gene polymorphism in patients with autosomal dominant polycystic kidney disease: effect on hypertension and ESRD.
383. Role of endothelin and nitric oxide in the pathogenesis of arterial hypertension in autosomal dominant polycystic kidney disease.
384. Milder presentation of recessive polycystic kidney disease requires presence of amino acid substitution mutations.
385. Genotype-renal function correlation in type 2 autosomal dominant polycystic kidney disease.
386. Unilateral autosomal dominant polycystic kidney disease with contralateral renal agenesis: a case report.
387. Kidney-specific inactivation of the KIF3A subunit of kinesin-II inhibits renal ciliogenesis and produces polycystic kidney disease.
388. Na transport in autosomal recessive polycystic kidney disease (ARPKD) cyst lining epithelial cells.
389. PKHDL1, a homolog of the autosomal recessive polycystic kidney disease gene, encodes a receptor with inducible T lymphocyte expression.
390. Ruptured giant liver cyst: a rare cause of acute abdomen in a haemodialysis patient with autosomal dominant polycystic kidney disease.
391. Hand-assisted bilateral nephrectomy in a patient with adult polycystic kidney disease.
392. Renal cyst ablation with n-butyl cyanoacrylate and iodized oil in symptomatic patients with autosomal dominant polycystic kidney disease: preliminary report.
393. Polycystic kidney disease as a result of loss of the tuberous sclerosis 2 tumor suppressor gene during development.
394. ETA receptor blockade induces tubular cell proliferation and cyst growth in rats with polycystic kidney disease.
395. Molecular cytogenetic aberrations in autosomal dominant polycystic kidney disease tissue.
396. Gross hematuria rapidly deteriorated renal function in a patient with polycystic kidney disease and Klippel-Trenaunay-Weber syndrome.
397. Trichosporon loubieri infection in a patient with adult polycystic kidney disease.
398. Spectrum of mutations in the gene for autosomal recessive polycystic kidney disease (ARPKD/PKHD1).
399. Alterations in renal cytosolic phospholipase A2 and cyclooxygenases in polycystic kidney disease.
400. Polycystic kidney disease associated with cervical arteriovenous shunt and bilateral jugular vein occlusion.
401. The effects of antihypertensive agents on the survival rate of polycystic kidney disease in Han:SPRD rats.
402. Cleavage of polycystin-1 requires the receptor for egg jelly domain and is disrupted by human autosomal-dominant polycystic kidney disease 1-associated mutations.
403. Infertility in adults with polycystic kidney disease.
404. Atubular glomeruli in a rat model of polycystic kidney disease.
405. Images in clinical medicine. End-stage autosomal dominant polycystic kidney disease.
406. The effect of caffeine on renal epithelial cells from patients with autosomal dominant polycystic kidney disease.
407. Kidney injury molecule-1 expression in murine polycystic kidney disease.
408. Multiorgan mRNA misexpression in murine autosomal recessive polycystic kidney disease.
409. The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia.
410. Polycystic kidney disease in patients on the renal transplant waiting list: trends in hematocrit and survival.
411. Genetics and pathogenesis of polycystic kidney disease.
412. Characterization of a major modifier locus for polycystic kidney disease (Modpkdr1) in the Han:SPRD(cy/+) rat in a region conserved with a mouse modifier locus for Alport syndrome.
413. Trans-heterozygous Pkd1 and Pkd2 mutations modify expression of polycystic kidney disease.
414. Intestinal obstruction in autosomal dominant polycystic kidney disease.
415. Renal reduction therapy for patients with autosomal dominant polycystic kidney disease.
416. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study.
417. The Jeremiah Metzger Lecture. Polycystic kidney disease: old disease in a new context.
418. The polycystic kidney disease-1 promoter is a target of the beta-catenin/T-cell factor pathway.
419. Activity and functional significance of the renal kallikrein-kinin-system in polycystic kidney disease of the rat.
420. Intracranial aneurysms and dolichoectasia in autosomal dominant polycystic kidney disease.
421. CPG70 is a novel basic metallocarboxypeptidase with C-terminal polycystic kidney disease domains from Porphyromonas gingivalis.
422. The position of the polycystic kidney disease 1 (PKD1) gene mutation correlates with the severity of renal disease.
423. c-myc-induced apoptosis in polycystic kidney disease is independent of FasL/Fas interaction.
424. Polycystic kidney disease and late peritoneal leakage in CAPD: are they related?
425. Caspases, Bcl-2 proteins and apoptosis in autosomal-dominant polycystic kidney disease.
426. Oxidant stress and reduced antioxidant enzyme protection in polycystic kidney disease.
427. Dialysis-associated acquired cystic kidney disease imitating autosomal dominant polycystic kidney disease in a patient receiving long-term peritoneal dialysis.
428. Cystin, a novel cilia-associated protein, is disrupted in the cpk mouse model of polycystic kidney disease.
429. Impaired endocytosis may represent an obstacle to gene therapy in polycystic kidney disease.
430. Mutation detection for exons 2 to 10 of the polycystic kidney disease 1 (PKD1)-gene by DGGE.
431. Modifier effect of ENOS in autosomal dominant polycystic kidney disease.
432. Tissue and cellular localization of a novel polycystic kidney disease-like gene product, polycystin-L.
433. Polycystic kidney disease as a new risk factor for coronary events.
434. Novel mutations of PKD1 gene in Chinese patients with autosomal dominant polycystic kidney disease.
435. Management of cerebral aneurysms in autosomal dominant polycystic kidney disease.
436. Angiotensin-converting enzyme activity and the ACE Alu polymorphism in autosomal dominant polycystic kidney disease.
437. PET-CT-guided percutaneous puncture of an infected cyst in autosomal dominant polycystic kidney disease: case report.
438. Pain management in polycystic kidney disease.
439. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease.
440. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension.
441. Early development of polycystic kidney disease in transgenic mice expressing an activated mutant of the beta-catenin gene.
442. A novel inhibitor of tumor necrosis factor-alpha converting enzyme ameliorates polycystic kidney disease.
443. Novel PKD1 deletions and missense variants in a cohort of Hellenic polycystic kidney disease families.
444. A child with polycystic kidney disease: do we have to care about associated malformations?
445. Lesson of the week: Causes of haematuria in adult polycystic kidney disease.
446. Thoracic aortic dissection in a patient with autosomal dominant polycystic kidney disease.
447. Pseudotuberculous pyelonephritis in a patient with autosomal dominant polycystic kidney disease undergoing long-term haemodialysis.
448. Autosomal recessive polycystic kidney disease in adulthood.
449. Angiogenesis in autosomal-dominant polycystic kidney disease.
450. Polycystic kidney disease induced in F(1) Sprague-Dawley rats fed para-nonylphenol in a soy-free, casein-containing diet.
451. Prevalence of autosomal-dominant polycystic kidney disease in Alentejo, Portugal.
452. Treatment prospects for autosomal-dominant polycystic kidney disease.
453. Autosomal dominant polycystic kidney disease unlinked to the PKD1 and PKD2 loci presenting as familial cerebral aneurysm.
454. Progression of autosomal-dominant polycystic kidney disease in children.
455. Role of CFTR in autosomal recessive polycystic kidney disease.
456. Polycystin-2, the protein mutated in autosomal dominant polycystic kidney disease (ADPKD), is a Ca2+-permeable nonselective cation channel.
457. An endocytosis defect as a possible cause of proteinuria in polycystic kidney disease.
458. Polycystic kidney disease: In danger of being X-rated?
459. Segment-specific c-ErbB2 expression in human autosomal recessive polycystic kidney disease.
460. Bilineal disease and trans-heterozygotes in autosomal dominant polycystic kidney disease.
461. Hypertension in autosomal-dominant polycystic kidney disease: early occurrence and unique aspects.
462. Human adolescent nephronophthisis: gene locus synteny with polycystic kidney disease in pcy mice.
463. The vasculopathy of autosomal dominant polycystic kidney disease: insights from animal models.
464. Volumetric determination of progression in autosomal dominant polycystic kidney disease by computed tomography.
465. CF gene and cystic fibrosis transmembrane conductance regulator expression in autosomal dominant polycystic kidney disease.
466. New rat model that phenotypically resembles autosomal recessive polycystic kidney disease.
467. Dietary betaine modifies hepatic metabolism but not renal injury in rat polycystic kidney disease.
468. Renal and extrarenal autosomal dominant polycystic kidney disease.
469. Polycystin-1, the product of the polycystic kidney disease 1 gene, co-localizes with desmosomes in MDCK cells.
470. Chlamydomonas IFT88 and its mouse homologue, polycystic kidney disease gene tg737, are required for assembly of cilia and flagella.
471. Citrate therapy for polycystic kidney disease in rats.
472. Selective angiography of cerebral aneurysm using gadodiamide in polycystic kidney disease with renal insufficiency.
473. Altered expression of type II sodium/phosphate cotransporter in polycystic kidney disease.
474. Development of autosomal recessive polycystic kidney disease in BALB/c-cpk/cpk mice.
475. [Congenital hepatic fibrosis and autosomal recessive polycystic kidney disease].
476. Association of the ACE gene polymorphism with the progression of autosomal dominant polycystic kidney disease.
477. Sonographic pattern of recessive polycystic kidney disease in young adults. Differences from the dominant form.
478. Liver involvement in autosomal-dominant polycystic kidney disease: therapeutic dilemma.
479. Progressive renal fibrosis in murine polycystic kidney disease: an immunohistochemical observation.
480. In vivo interaction of the adapter protein CD2-associated protein with the type 2 polycystic kidney disease protein, polycystin-2.
481. The hypertensive young lady with renal cysts--it is not always polycystic kidney disease.
482. Quantification and longitudinal trends of kidney, renal cyst, and renal parenchyma volumes in autosomal dominant polycystic kidney disease.
483. Endothelium-dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease.
484. Genetic linkage study of family members of a patient with adult polycystic kidney disease.
485. cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells.
486. Strong homophilic interactions of the Ig-like domains of polycystin-1, the protein product of an autosomal dominant polycystic kidney disease gene, PKD1.
487. Endotoxin and nanobacteria in polycystic kidney disease.
488. Autosomal recessive polycystic kidney disease: radiologic-pathologic correlation.
489. [Active uremia therapy in autosomal dominant polycystic kidney disease].
490. The ACE insertion/deletion polymorphism has no influence on progression of renal function loss in autosomal dominant polycystic kidney disease.
491. Transepithelial chloride secretion and cystogenesis in autosomal dominant polycystic kidney disease.
492. Genomic structure of the gene for the human P1 protein (MCM3) and its exclusion as a candidate for autosomal recessive polycystic kidney disease.
493. The polycystic kidney disease protein PKD2 interacts with Hax-1, a protein associated with the actin cytoskeleton.
494. Proximal tubular cysts in fetal human autosomal recessive polycystic kidney disease.
495. Compromised cytoarchitecture and polarized trafficking in autosomal dominant polycystic kidney disease cells.
496. An unbalanced submicroscopic translocation t(8;16)(q24.3;p13.3)pat associated with tuberous sclerosis complex, adult polycystic kidney disease, and hypomelanosis of Ito.
497. Diagnosis of tuberous sclerosis in a patient who presented with polycystic kidney disease.
498. A novel frameshift mutation (2436insT) produces an immediate stop codon in the autosomal dominant polycystic kidney disease 2 (PKD2) gene.
499. Genetic evidence for a trans-heterozygous model for cystogenesis in autosomal dominant polycystic kidney disease.
500. Autosomal dominant polycystic kidney disease-type 2. Ultrasound, genetic and clinical correlations.
501. Genetic localization of interacting modifiers affecting severity in a murine model of polycystic kidney disease.
502. Apical plasma membrane mispolarization of NaK-ATPase in polycystic kidney disease epithelia is associated with aberrant expression of the beta2 isoform.
503. Modification of polycystic kidney disease and fatty acid status by soy protein diet.